Generic drugmakers in China are waiting in the wings for Wegovy patent expiration

China may be the first country where Novo Nordisk loses patent protection for active ingredient semaglutide. 
Photo: Gregers Tycho
Photo: Gregers Tycho

Novo Nordisk is facing growing competition on the attractive Chinese market, where at least 11 generic variants of its diabetes drug Ozempic and weight loss treatment Wegovy are in development, Reuters reports.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading